Engaged Capital’s DexCom DXCM Stock Holding History

Engaged Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-240,000	Closed	-$2.94M	–	17
2017 Q3	$2.94M	Buy	+240,000	New	+$4.24M	0.36%	19

Other funds holding DXCM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Engaged Capital's DXCM Position: Q4 2017 in Review

Engaged Capital sold out of DexCom (DXCM) in Q4 2017, closing a stake of 240,000 shares — an estimated $2.94M sold.

Engaged Capital first reported a position in DXCM in Q3 2017 and held it in 1 quarter. The position peaked at $2.94M in Q3 2017. 273 funds tracked by Wall St. Rank hold DXCM as of Q4 2017.

Engaged Capital reported no remaining DexCom position as of Q4 2017 after selling out during the quarter.
Engaged Capital sold 240,000 DexCom shares in Q4 2017, an estimated $2.94M.
Engaged Capital first reported a position in DexCom in Q3 2017 and held it in 1 quarter.
Engaged Capital's DexCom position peaked at $2.94M in Q3 2017.
273 funds tracked by Wall St. Rank held DexCom as of Q4 2017.

Based on Engaged Capital's 13F filing for Q4 2017, filed 14 Feb 2018.